Try our beta test site
123 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND Everolimus [TREATMENT]
Show Display Options
Rank Status Study
1 Completed Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: everolimus;   Genetic: molecular response by PCR
2 Completed Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Condition: CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
Interventions: Drug: AEB071;   Drug: Everolimus
3 Unknown  Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma
Condition: Recurrent or Refractory Primary CNS Lymphoma
Intervention: Drug: temsirolimus
4 Completed
Has Results
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
Condition: Lymphoma
Interventions: Drug: Panobinostat;   Drug: Everolimus
5 Completed Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Condition: Non-Hodgkins Lymphoma
Interventions: Drug: Velcade;   Drug: Temsirolimus
6 Terminated Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy
Condition: Lymphoma
Intervention: Drug: everolimus
7 Withdrawn Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Condition: Cutaneous T-cell Lymphoma (CTCL)
Intervention: Drug: Sirolimus 0.1% Ointment
8 Recruiting Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: temsirolimus
9 Unknown  Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention: Drug: Temsirolimus
10 Terminated
Has Results
Everolimus in Treating Cutaneous T-cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: Everolimus
11 Completed
Has Results
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Condition: Hodgkin Lymphoma
Intervention: Drug: Everolimus (RAD001)
12 Active, not recruiting Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
Conditions: Follicular Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Temsirolimus, Rituximab, Bendamustin
13 Completed A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Everolmus
14 Completed S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: everolimus;   Drug: lapatinib ditosylate
15 Terminated Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Conditions: 714leukemia;   Lymphoma
Interventions: Drug: Bortezomib;   Drug: Everolimus
16 Completed
Has Results
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
Condition: Lymphoma
Interventions: Drug: Temsirolimus (CCI-779);   Drug: Investigator's choice
17 Completed Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma
Condition: B-cell Lymphoma Refractory
Interventions: Drug: Inotuzumab Ozogamicin;   Drug: Temsirolimus
18 Completed Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001;   Drug: Placebo
19 Completed The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas
Condition: Non-Hodgkin's Lymphomas
Intervention: Drug: Everolimus and rituximab
20 Active, not recruiting Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: everolimus;   Drug: prednisone;   Drug: vincristine sulfate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.